XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Stockholders’ Equity (Tables)
 6 Months Ended
Jun. 28, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Employee Stock-Based Compensation Expense
We allocated the stock-based compensation expense for our equity incentive plans and our Amended ESPP as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Research and development$9,178 $9,589 $13,070 $12,841 
Selling, general and administrative16,176 15,311 31,397 28,720 
Total stock-based compensation expense$25,354 $24,900 $44,467 $41,561 
Stock-based compensation expense for each type of award under our equity incentive plans and Amended ESPP were as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Stock options$1,524 $1,877 $3,262 $4,084 
Restricted stock units22,164 19,757 37,598 32,364 
Performance stock units1,097 1,872 1,824 2,666 
Employee stock purchase plan
569 1,394 1,783 2,447 
Total stock-based compensation expense$25,354 $24,900 $44,467 $41,561 
Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions
We used a Monte Carlo simulation model and the following weighted-average assumptions to determine the weighted-average grant date fair value of $20.19 per share for the 2024 TSR-based RSUs:
Fair value of Exelixis common stock on grant date
$21.71 
Expected volatility
36.68 %
Risk-free interest rate
4.42 %
Dividend yield
— %